BR112013001136A2 - processo de análise de uma amostra de sangue de um sujeito para a presença de um marcador de doença - Google Patents

processo de análise de uma amostra de sangue de um sujeito para a presença de um marcador de doença

Info

Publication number
BR112013001136A2
BR112013001136A2 BR112013001136A BR112013001136A BR112013001136A2 BR 112013001136 A2 BR112013001136 A2 BR 112013001136A2 BR 112013001136 A BR112013001136 A BR 112013001136A BR 112013001136 A BR112013001136 A BR 112013001136A BR 112013001136 A2 BR112013001136 A2 BR 112013001136A2
Authority
BR
Brazil
Prior art keywords
disease marker
analyzing
subject
blood sample
disease
Prior art date
Application number
BR112013001136A
Other languages
English (en)
Other versions
BR112013001136B1 (pt
Inventor
Rolf Jonas Nilssom
Thomas Würdinger
Original Assignee
Stichting Vu Vumc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Vu Vumc filed Critical Stichting Vu Vumc
Publication of BR112013001136A2 publication Critical patent/BR112013001136A2/pt
Publication of BR112013001136B1 publication Critical patent/BR112013001136B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

processo de análise de uma amostra de sangue de um sujeiro para a presença de um marcador de doença. a presente invenção refere-se a um processo de análise de uma amostra de sangue de um sujeito para a presença de um marcador de doença, o dito processo compreendendo as etapas de a) extração de ácido nucléico de células de sangue anucleadas na dita amostra de sangue para prover uma fração de ácido nucléico extraída com células de sangue anucleadas, e b) análise de dita fração de ácido nucléico de células de sangue anucleadas para a presença de um marcador de doença, onde o dito marcador de doença é uma mutação específica de doença em um gene de uma célula do dito sujeito, ou onde o dito marcador de doença é um perfil de expressão específico de doença de genes de uma células do dito sujeito.
BR112013001136-0A 2010-07-16 2011-07-15 Processos de análise para a presença de um marcador de câncer, do estágio da doença ou da eficácia de um tratamento de câncer, e dispositivo para diagnóstico de câncer BR112013001136B1 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US36483110P 2010-07-16 2010-07-16
EP10169897.5 2010-07-16
US61/364,831 2010-07-16
EP10169897 2010-07-16
EP11158912 2011-03-18
EP11158912.3 2011-03-18
EP11167973.4 2011-05-27
EP11167973 2011-05-27
PCT/NL2011/050518 WO2012008839A2 (en) 2010-07-16 2011-07-15 A method of analysing a blood sample of a subject for the presence of a disease marker

Publications (2)

Publication Number Publication Date
BR112013001136A2 true BR112013001136A2 (pt) 2016-07-05
BR112013001136B1 BR112013001136B1 (pt) 2020-12-15

Family

ID=45469975

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013001136-0A BR112013001136B1 (pt) 2010-07-16 2011-07-15 Processos de análise para a presença de um marcador de câncer, do estágio da doença ou da eficácia de um tratamento de câncer, e dispositivo para diagnóstico de câncer

Country Status (11)

Country Link
US (1) US10174364B2 (pt)
EP (1) EP2593787B1 (pt)
JP (2) JP6076901B2 (pt)
CN (1) CN103168235B (pt)
AU (1) AU2011277178B2 (pt)
BR (1) BR112013001136B1 (pt)
CA (1) CA2805586C (pt)
HK (1) HK1186767A1 (pt)
MX (1) MX351242B (pt)
SG (1) SG187101A1 (pt)
WO (1) WO2012008839A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG187101A1 (en) 2010-07-16 2013-02-28 Stichting Vu Vumc A method of analysing a blood sample of a subject for the presence of a disease marker
CA2830461C (en) * 2011-03-18 2021-06-29 Thomas Wurdinger A method of analysing a blood sample of a subject for the presence of a disease marker
KR20150023721A (ko) * 2012-06-15 2015-03-05 스트링 테라퓨틱스 Fsh, lh, hcg 및 bnp를 위한 현장 진단 기기에 의한 맞춤형 의료를 위한 방법 및 조성물
WO2014134790A1 (zh) * 2013-03-06 2014-09-12 广州百赫医疗信息科技有限公司 神经纤维瘤病pcr诊断试剂盒
AU2015249374A1 (en) 2014-04-24 2016-12-01 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
US10512402B2 (en) * 2015-04-22 2019-12-24 Board Of Trustees Of Northern Illinois University Non-invasive occular biomarkers for early diagnosis of diseases
WO2018151601A1 (en) * 2017-02-17 2018-08-23 Stichting Vumc Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets
US11667975B2 (en) * 2018-04-24 2023-06-06 Washington University Methods and systems for noninvasive and localized brain liquid biopsy using focused ultrasound
CN112094907B (zh) * 2019-06-18 2023-08-18 杭州太铭生物科技有限公司 外周血红细胞微核dna及其应用
CN113430264A (zh) * 2020-03-23 2021-09-24 南京梅傲红清生物科技有限公司 红细胞核酸在鉴定肿瘤的突变类型中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
US5185244A (en) 1989-12-08 1993-02-09 Emory University Genetic test for hereditary neuromuscular disease
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5719028A (en) 1992-12-07 1998-02-17 Third Wave Technologies Inc. Cleavase fragment length polymorphism
SE9400522D0 (sv) 1994-02-16 1994-02-16 Ulf Landegren Method and reagent for detecting specific nucleotide sequences
US5942391A (en) 1994-06-22 1999-08-24 Mount Sinai School Of Medicine Nucleic acid amplification method: ramification-extension amplification method (RAM)
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
WO2000063441A2 (en) * 1999-04-20 2000-10-26 Mitokor Single nucleotide polymorphisms in mitochondrial genes that segregate with alzheimer's disease
AU2002240745A1 (en) * 2001-03-07 2002-09-19 Andre Schuh Diagnosis and treatment of blood disorders
GB2380194B (en) * 2001-10-01 2005-06-22 Roger Michael Marchbanks A mitochondrial mutation associated with schizophrenia and increased oxidative stress
US6977162B2 (en) 2002-03-01 2005-12-20 Ravgen, Inc. Rapid analysis of variations in a genome
CN1922304A (zh) * 2003-10-31 2007-02-28 维特克公司 用于检测循环肿瘤和内皮细胞的血液测试样机和方法
EP1745145A4 (en) 2004-05-11 2008-03-26 Heptest Lab Inc COMPOSITIONS, KIT AND METHOD IN ONE STEP FOR MONITORING COMPOUNDS HAVING XA AND / OR ANTIFACTOR IIA ANTIFACTOR ACTIVITIES
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
ATE438856T1 (de) * 2005-06-22 2009-08-15 Univ Johns Hopkins Biomarker für eierstockkrebs: mit ctap3 verwandte proteine
US20070059774A1 (en) 2005-09-15 2007-03-15 Michael Grisham Kits for Prenatal Testing
US20070059781A1 (en) 2005-09-15 2007-03-15 Ravi Kapur System for size based separation and analysis
EP1931800A4 (en) 2005-09-15 2011-06-15 Artemis Health Inc SYSTEMS AND METHODS FOR ENRICHING ANALYTES
US20090042869A1 (en) 2007-06-20 2009-02-12 University Of Utah Research Foundation SIGNAL-DEPENDENT SPLICING OF TISSUE FACTOR PRE-mRNA IN PLATELET CELLS
US11634747B2 (en) 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
EP2336353A1 (en) 2009-12-17 2011-06-22 febit holding GmbH miRNA fingerprints in the diagnosis of diseases
SG187101A1 (en) 2010-07-16 2013-02-28 Stichting Vu Vumc A method of analysing a blood sample of a subject for the presence of a disease marker
CA2830461C (en) 2011-03-18 2021-06-29 Thomas Wurdinger A method of analysing a blood sample of a subject for the presence of a disease marker
EP2742150A1 (en) 2011-08-09 2014-06-18 Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg A method of analysing a blood sample of a subject for the presence of a foetal disease or condition marker

Also Published As

Publication number Publication date
CA2805586C (en) 2020-09-01
US20130196873A1 (en) 2013-08-01
MX2013000606A (es) 2013-06-28
CN103168235A (zh) 2013-06-19
EP2593787A2 (en) 2013-05-22
WO2012008839A2 (en) 2012-01-19
CN103168235B (zh) 2016-01-13
AU2011277178A2 (en) 2013-02-07
JP2017018099A (ja) 2017-01-26
WO2012008839A3 (en) 2012-03-01
JP6076901B2 (ja) 2017-02-15
MX351242B (es) 2017-10-05
HK1186767A1 (zh) 2014-03-21
US10174364B2 (en) 2019-01-08
AU2011277178A1 (en) 2013-01-31
JP6171057B2 (ja) 2017-07-26
EP2593787B1 (en) 2018-07-04
JP2013534429A (ja) 2013-09-05
SG187101A1 (en) 2013-02-28
CA2805586A1 (en) 2012-01-19
BR112013001136B1 (pt) 2020-12-15
WO2012008839A9 (en) 2012-05-03
AU2011277178B2 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
BR112013001136A2 (pt) processo de análise de uma amostra de sangue de um sujeito para a presença de um marcador de doença
BR112013023960A2 (pt) método de análise de uma amostra de sangue de um indivíduo para a presença de um marcador de doença
Hu et al. Simultaneous profiling of transcriptome and DNA methylome from a single cell
Farlik et al. Single-cell DNA methylome sequencing and bioinformatic inference of epigenomic cell-state dynamics
Wang et al. miRExpress: analyzing high-throughput sequencing data for profiling microRNA expression
Hu et al. MicroRNA expression and regulation in human, chimpanzee, and macaque brains
Yang et al. Evolution of the mir-181 microRNA family
NZ593628A (en) Genetic variants useful for risk assessment of thyroid cancer using rs944289
MX2012002411A (es) Metodos de ensayo para el mdv-1.
Maciel et al. Weighted gene co-expression analyses point to long non-coding RNA hub genes at different Schistosoma mansoni life-cycle stages
NZ598009A (en) Genetic markers associated with risk of diabetes mellitus
WO2009102748A3 (en) Alternatively transcribed genes associated with schizophrenia
WO2012112955A3 (en) Methods for identifying subjects with a genetic risk for developing iga nephropathy
EP2576778A4 (en) TRANSGENE REPORTER SYSTEM FOR DETERMINING EXPRESSION PROFILES AND CONTROL MECHANISMS FOR ALTERNATIVE SPLASHING IN MAMMALIAN ORGANISMS
Bressan et al. The Foundational data initiative for Parkinson’s disease (FOUNDIN-PD): enabling efficient translation from genetic maps to mechanism
Ghorbian Micro-RNAs, next-generation molecular markers in male infertility field
Marcińska et al. Genetic identification of Cannabis varieties based on marker STR analysis: Preliminary studies
US20220162708A1 (en) Physical characterization of telomere (pct)
Campanaro et al. Do high throughput sequencing techniques provide the same phylogenetic result in anaerobic digestion system?
Polli et al. High density canine 170,000 SNPs array for recessive trait mapping in a canine pure breed
Maolmhuaidh et al. Clinical data warehouses for disease diagnosis: A focus on exosomal MicroRNA biomarkers
Lanubile et al. RNA-Sequencing as a tool for the analysis of the pathosystem maize-Fusarium verticillioides.
De Meulemeester et al. Landmark based geometric morphometrics analysis of wing shape as a tool for Bombus s. str. taxonomy (Hymenoptera: Apidae)
Dieset Response to Li and Su Letter
LO PRESTI CANDIDATE GENE ASSOCIATION ANALYSIS IN RESPIRATORY DISEASES–THE GEIRD PROJECT

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: STICHTING VUMC (NL)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/07/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2679 DE 10-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.